First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma
- 20 June 2007
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 79 (3) , 240-243
Abstract
In vitro statins overcome cell adhesion‐mediated drug resistance at non‐toxic concentrations that are achievable in humans by standard dose simvastatin. A pilot phase‐II trial was initiated to determine feasibility and antimyeloma efficacy. In six myeloma patients refractory to two cycles of bortezomib or bendamustine simvastatin was concomitantly administered during further two cycles. The therapy was well tolerated without grade 3/4 toxicity. Intrapatient (cycles I/II vs. III/IV) and interpatient comparison (vs. ten patients without simvastatin) showed reduction of drug resistance by inhibition of HMG‐CoA‐reductase. In summary, this is the first phase II experience to study antimyeloma activity of statins in humans.Keywords
This publication has 7 references indexed in Scilit:
- Synergistic antimyeloma effects of zoledronate and simvastatinAnti-Cancer Drugs, 2006
- The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion–mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinaseBlood, 2004
- Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levelsBlood, 2003
- The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cellsLeukemia, 2002
- New insights into the pharmacodynamic and pharmacokinetic properties of statinsPharmacology & Therapeutics, 1999
- Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell LinesBlood, 1999
- Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoproteinAnti-Cancer Drugs, 1994